AI brief of an SEC Form 8-K · Edgewell Personal Care (EPC)

Edgewell to sell Feminine Care business to Essity for $340 million in cash

Mixed Impact 4 of 5 m&a Written later

Edgewell Personal Care agreed on November 12, 2025 to sell its Feminine Care segment to Essity for $340 million in cash, subject to customary adjustments. The closing is expected in the first quarter of calendar 2026, pending regulatory approvals, and the company expects the sale to reduce its adjusted EPS and adjusted EBITDA on an annualized basis, net of transition service income.

Key points

  • Buyer: Essity Aktiebolag (publ); consideration is $340 million in cash, subject to adjustments for inventory, indebtedness and other items
  • Expected closing in the first quarter of calendar 2026; the outside date is May 12, 2026, with extensions to as late as November 12, 2026
  • Company expects an annualized impact of approximately $0.40 to $0.50 in adjusted EPS and $35 million to $45 million in adjusted EBITDA, net of transition services income
  • Net proceeds, after taxes and transaction costs, are intended primarily to strengthen the balance sheet; the company would receive a $15 million termination fee in certain circumstances

The filing

CompanyEdgewell Personal Care (EPC)
Form8-K, current report
Filed with the SECNov 13, 2025, 6:03 AM ET
Accession number0001628280-25-051814

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 13, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.